Author

D. Mielke

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 3

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:proteomics· 3 Research Focus:drug response / drug discovery· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1

Frequent Co-Authors

B. F. Haynes· 3 shared G. Ferrari· 3 shared K. O. Saunders· 3 shared A. Eaton· 2 shared A. Newman· 2 shared D. Montefiori· 2 shared D. W. Cain· 2 shared K. Mansouri· 2 shared

Activity by Year

2019-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

B. F. Haynes

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Engineered Immunogens to Elicit Antibodies Against Conserved Coronavirus Epitopes

B. Kapingidza, D. J. Marston, C. Harris, D. Wrapp, K. Winters, D. Mielke, L. Xiaozhi, Q. Yin, A. Foulger, R. Parks, M. Barr, A. Newman, A. Schaefer, A. Eaton, J. M. Flores, , M. L. Azoitei

This study designs engineered immunogens targeting conserved coronavirus epitopes to elicit broad-spectrum antibodies, showing protection in mice against live virus challenge.

bioRxiv · Feb 27, 2023Immunology

Breadth of SARS-CoV-2 Neutralization and Protection Induced by a Nanoparticle Vaccine

D. Li, D. R. Martinez, A. Schäfer, H. Chen, M. Barr, L. L. Sutherland, E. Lee, R. Parks, D. Mielke, W. Edwards, A. Newman, K. W. Bock, M. Minai, B. M. Nagata, M. Gagne, , B. F. Haynes

This study shows a nanoparticle vaccine induces broad neutralizing antibodies against multiple SARS-CoV-2 variants and protects non-human primates and mice from viral challenges.

bioRxiv · Jan 26, 2022Immunology

Boosting with ALVAC-HIV and AIDSVAX B/E enhances Env constant region 1 and 2 antibody-dependent cellular cytotoxicity

D. Easterhoff, J. Pollara, K. Luo, W. D. Tolbert, B. Young, D. Mielke, S. Jha, R. J. O'Connell, S. Vasan, J. Kim, N. Michael, J.-L. Excler, M. L. Robb, S. Rerks-Ngarm, J. Kaewkungwal, , G. Ferrari

The paper shows that boosting RV144 vaccine recipients with ALVAC-HIV and AIDSVAX B/E increases C1C2-specific antibody-dependent cellular cytotoxicity breadth and potency.

bioRxiv · May 9, 2019 · PreprintImmunology